Our Research

Our current colorectal cancer research


Implementation of validated cancer-associated blood-based biomarkers in:

  • Improved CRC screening
  • Improved screening for extra-colonic malignancies
  • Early detection of recurrent disease in patients treated for CRC
  • Individualized chemo-/radio-/immunotherapy




  • Early detection of neoplastic diseases—improved survival
  • Detection of benign neoplastic lesions that may be resected/excised
    leading to a reduction of the amount of cancer diagnoses
  • Reduction of unnecessary examinations (colonoscopies/scannings)—improved health economy




Four research tracks




Since 1990 the overall research has been on colorectal cancer and other neoplastic non-bowel lesions with focus on:

  • Tumorigenesis
  • Invasion and metastasis processes
  • Treatment
  • Recurrence
  • Prognosis
  • Prediction
  • Selection
  • Monitoring


Presently achieved overall results

The research has currently identified blood-based biomarkers that may identify subjects with:

  • Colorectal cancer – all stages
  • Adenomas – all categories
  • Extra-colonic malignancies
  • High-risk of developing subsequent malignancy


Background for our current research

Colorectal cancer (CRC= bowel cancer) is an age related disease.
Symptoms with the disease are often not recognized until the late stages of the disease,
where complete cure is hardly achievable.

  • Annually, approximately 1,900 Danes (2014-2016) die from the disease—and > 5.400 new diagnoses are established.
    At present, about 40.000 Danes have the diagnosis of which 60-65% are estimated to survive > 5 years
  • Coloectal Cancer is curable if diagnosed in the early stages
  • Population screening has been implemented as part of the entire dealing with the disease


The current screening in Denmark

  • At present, the screening in Denmark is based on a FIT test (a test for occult blood in feces),
    where a FIT-positive screening-test  will activate an offer of a subsequent colonoscopy
  • The FIT test has a sensitivity of 75% at 90–95% specificity—thus,at present, being the most cost/effective model for the Danish screening
  • The current compliance rate is 60-65%
  • Just 45-50% of those with neoplastic bowel lesions will be identified by the FIT screening
  • I.e. 50-55% of those in the screening relevant population with a neoplastic bowel lesion is not identified—mostly due to the lack of compliance in the general screening
  • The success of The Danish CRC-screening with findings of many with the disease as well as adenomas (premalignant lesions) plus the reduction in 2018 of the screening interval from 4 to just 2 years has led to waiting time for colonoscopy.
    To day the overall demand of colonoscopies (screening, diagnostic and adenoma control colonoscopies) far exceeds the Danish examination capacity, in total, and the waiting period for screening derivatives as well as the diagnostic colonoscopies,often exceeds the statutory 14 days.



Additional information:

Research Areas          


Print Friendly, PDF & Email


ColoRectal Cancer Research

Gastroenheden, Hvidovre Hospital

Kettegård Allé 30

2650 Hvidovre

Email: info@colorectalcancer.dk